Medicare Urged To Allow Home Infusion Plan With Direct Buying, Billing By Outside Providers
Manufacturers seek additional flexibility from Medicare to facilitate home infusions as surveys indicate patient visits to physician offices have dropped by 40% to 68% in recent weeks, signaling a decline in adherence for physician-administered drugs.
You may also be interested in...
Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.
Plan to allow broader coverage for home infused drugs during the COVID-19 emergency prompts opposition from providers seeking an approach more in line with commercial insurance practices.
It’s not quite the rebate rule, but final reg aims for ‘a reduction in the use of rebates and other price concessions’ driven by the transparency requirement and broad definitions. PCMA warns that ‘mandating an increased level of disclosure for this information could result in higher prescription drug prices for consumers.’